verywellhealth9d
Cobenfy: The First New Schizophrenia Drug in Decades
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
FDA Approves Potentially Groundbreaking Schizophrenia Drug
On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...
F.D.A. Approves the First New Schizophrenia Drug in Decades
Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.
FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades
The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S. living with ...
FDA approves a novel drug for schizophrenia, a potential ‘game changer’
The approval comes less than a year Bristol Myers Squibb paid $14 billion to acquire the developer of the drug, Karuna ...
Yahoo Finance13d
Bristol Myers schizophrenia drug, the first of its kind, approved by FDA
Recommended Reading Psychiatry drugs finally have ... than a dozen antipsychotics for schizophrenia, and many have ...
Bristol Myers wins US FDA approval for new type of schizophrenia drug
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
New schizophrenia drug ‘could change the lives of millions of people’
A groundbreaking new drug to treat schizophrenia called Cobenfy, owned by pharmaceutical firm Bristol Myers Squibb, has been ...
WVTF12d
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
Why approval of KarXT, the first new drug for schizophrenia in decades, is a big deal
After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...
MM&M12d
Bristol Myers Squibb wins FDA approval for first new schizophrenia drug in 30 years
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.